It is increasingly likely that you or someone you know has participated in a dry month, going alcohol-free. You may also have noticed more non-alcoholic options appearing on restaurant menus or at your local liquor store. Beyond the anecdotal, there is growing evidence of a decline in alcohol consumption. Changing attitudes towards drinking present some positives: reduced alcohol intake is associated with better health which can lower healthcare costs.
None of this has been overlooked by investors: with few exceptions, alcohol stocks have sold off solidly over the past several months.
In today’s note, we explore opportunities to underweight and/or short companies in an industry that is primed for overhaul.
Troubled Waters: The Challenges for the Alcoholic Beverage Industry
In developed nations, drinking has long been a part of the cultural fabric. However, younger generations are scaling back.
Within a decade, the share of American college students that abstain from drinking alcohol increased from 20% to 28%. In the U.S., only 60% of those aged 18 to 34 drink alcohol, compared to 70% in those aged 35 to 54 (see chart).
It was a long-held view that alcohol in moderation was not dangerous to health, and in some instances even heart healthy. This too is changing, as a growing body of research shows links with inclined risk of cancer. Nearly 20 years ago, a U.S. survey showed 25% of respondents perceived drinking in moderation as good for health. That has since declined to a low of 8%. In 2026, Ireland will become the first country to include cancer warnings on the labels of alcoholic beverages, similar to what is done for cigarettes. The tactic is also under consideration by other nations; broad adoption could have important consequences for the industry.
Furthermore, there may be options beyond sheer willpower to cut back on booze. One recent study suggests that semaglutide (weight loss drugs) could assist individuals in drinking less. Greater access to these drugs could have repercussions beyond snacks and fast food (please see our note, You Can Have Your Cake and Eat It Too, November 16, 2023), especially if deployed as a treatment for alcohol abuse.
Finally, the budding structural decline in alcohol consumption is not just a developed economy phenomenon. Although the picture is not uniform across developing economies, data from the World Health Organization (WHO) shows that annual per capita alcohol consumption is declining in every region of the world. Of course, developing countries with very high population growth rates can still be interesting markets for some alcohol producers, because even if individual consumers less, the consumer base may still grow. However, investors need to be cognizant that the trend away from alcohol is globally entrenched and it is not at all clear that EM consumption will offset the decline elsewhere in the world.
Moreover, even if EM alcohol consumption is robust, it is hardly clear that the incumbents, i.e. multinationals with strong brand recognition, will benefit. The alcohol industry is not immune to an increasingly hostile global trade backdrop. European spirit-makers are currently in the crosshairs of Chinese policymakers in revenge for new European tariffs on Chinese EVs. Spirit-makers are especially vulnerable to this development, since they tend to be more exposed to sales in these countries relative to the major developed market beer producers.
Faced with this decline in demand for their products, alcohol producers have struggled to raise prices relative to other consumer prices. The chart below shows the evolution of U.S. consumer price inflation; from 2000 to 2015, alcohol prices always rose in line or faster than overall prices. However, since 2015, alcohol price inflation has failed to keep pace.
Material Risks for the Alcoholic Beverage Industry
Using a double materiality framework, we classify alcoholic beverage products as having negative impact, substantiated by health issues and problems of dependence. Operationally, we align our analysis with the SASB materiality framework and see ingredient sourcing and water management as the most material environmental risks faced by producers. The availability and cost of grains and other agricultural inputs will be impacted by climate change and water is also indispensable to the production of alcoholic beverages. Even large scale brewers like Anheuser-Busch and Heineken, who are recognized for their efficiency need roughly 3 litres of water to produce 1 litre of beer.
Spirit-makers are overall less water intensive than beer producers and have significantly less total water usage. However, there is a wide range in water efficiency across major distilleries, with Remy Cointreau being most efficient and Campari Group (Davide-Campari-Milano) the laggard. Conversely, there is little distinction between the major beer producers in terms of water efficiency.
Note that in our list of public companies, Treasury Wine Estates has the poorest water efficiency. This is not surprising since growing grapes is very water intensive. The company’s larger water footprint reflects the cultivation of ingredients while most distillers and brewers purchase raw ingredients.
Constellation Brands generates 15% of revenues from wine and 82% from beer. Along with Treasury Wine Estates, it is the only other company from our list without a water efficiency target – a concerning oversight given these two companies operate in water-stressed areas like Australia, California and Mexico. Brewers have a lower margin business, with water being a major input cost – this makes the lack of a water efficiency goal a significant oversight on the part of Constellation Brands.
With regards to ESG scores, Constellation Brands stands out as a laggard with the lowest overall rank and being at the 50th percentile relative to its industry. There is little distinction between the other beermakers, with all companies within the top quintile. The spirit-makers exhibit a greater divergence: Diageo and Pernod Ricard take top ranks (even higher than the brewers), while Campari Group, Brown Forman and Becle lag. We expect beer companies will have an easier time adapting to seltzers or non-alcoholic drinks than their distiller counterparts; we therefore focus the remainder of our analysis on distillers and Constellation Brands.
Identifying Short Candidates
Having identified short candidates based on material sustainability risks, we now assess according to three factors that influence the price of distillery stocks: brand value, potential for acquisition, and overall efficiency of capital allocation and operations.
Brand value: Structural changes in consumer preferences means that there is more uncertainty about whether brands can hold their value. Almost all of the major distillery companies have seen an erosion in the value of their intangible assets as a percentage of total assets over the past five years (by 5% on average for 5 out of the 7 companies); there are no obvious catalysts for a reversal in this trend.
Acquisitions: One way to address a stagnating demand backdrop is through acquisition. Since building new brands is capital intensive and time consuming, acquiring established brands can fast track growth. We expect consolidation attempts will continue, although much has already occurred; all of the major distillery brands have been involved in acquisitions over the past ten years and each company already operates between 8 and 26 main brands. Given this backdrop, the size and pace of deals may be underwhelming going forward and implies that the impact on the incremental value will be smaller.
Capital Allocation and Operational Efficiency: The other way to create value is to improve the efficiency of capital allocation and operations. We use the invested capital turnover to evaluate capital allocation efficiency as it measures the amount of sales per unit of invested capital. All of the major alcohol companies we analysed exhibit declining investment capital turnover in the past five years with Becle and Remy Cointreau showing the worst efficiency in this regard.
For operational efficiency, we examine profit per unit of revenue via the net operating profit after tax NOPAT) margin. Among these companies, Remy Cointreau and Constellation Brands show some improvement in their operational efficiency over the years while Brown-Forman, Becle and David Campari-Milano worsened. This aligns with our sustainability analysis above; as companies that are better managing material risks like water have better operational results.
Plotting these two metrics informs on the return on invested capital (ROIC). In the chart below, the companies appearing in the top right have a relatively high ROIC, suggestive of a competitive advantage in cost leadership and product differentiation whereas Becle and Remy Cointreau have a weaker ROIC, meaning they are more at risk of losing market share. This is evidenced in their current stock valuations.
Shorting the Laggards: Timing Is Everything
Many of the major distillery stock prices have already been beaten down: along with structural headwinds identified in this note, producers have been faced with supply chain issues, a post-COVID slowdown in sales, and higher input cost pressure.
As a result, many companies are now trading at relatively cheap valuations (for example Becle, Brown-Forman and Remy Cointreau now have P/Es in the low 20s compared to over 30 at the start of the year).
We have high conviction that the structural backdrop for distillery stocks will continue to erode, thus making fertile ground for short opportunities in the long-term. However, in the short term, the current risk/reward profile suggests investors should wait for a bounce before getting involved.
In our last macro update (March 27, 2024), we had argued that the rate backdrop had become relatively benign for equity markets and that investors should begin to reflect on sector implications of a potential Trump presidency. The interest rate environment was indeed calm over the past six months: the Fed is on the cusp of its first interest rate reduction in over four years and has managed to stay very aligned with financial market participants’ expectations. However, whether the Fed can continue to deliver the rate cuts that are expected after September still depends on inflation. While there is more and more indication of lagging economic activity (in particular, we highlight below the impact of worsening credit conditions for consumers), the Fed can only provide stimulus if progress toward lowering inflation to 2% is sufficient. The most recent data was not encouraging in this regard; August data shows that progress at bringing down core CPI has stalled and prices continued to rise over the summer at over 3% annually.
On this basis, it’s hard to see how the Fed moves to a more accommodative stance barring a severe weakening (contraction) in economic growth. The bottom line is that contrary to the past six months when the Fed and market expectations of interest rate policy have been well aligned, odds are rising that policymakers will be unable to deliver on market expectations for rate cuts of 75 – 150 bps by year end.
Meanwhile, judging by the election betting markets after Tuesday’s Presidential debate, the likelihood is increasing for a Democratic win, reducing the allure of the “Trump trade” (i.e. overweight positions in USD, prisons, banks and oil companies).
From a sustainability perspective, the debate bolstered our suspicion that Harris is unlikely to make bold moves regarding major issues like climate change, climate adaptation and health care. Climate change was nary discussed, except to underscore that Harris would not ban fracking. On healthcare, she promised to “strengthen” Obamacare and to keep in place the Biden’s administration $2,000 cap on out-of-pocket prescription drug costs, which is slated to take effect for Medicare enrollees in 2025.
In terms of overall government spending, the debate confirmed our view that irrespective of the election result, U.S. fiscal spending will be neither headwind nor tailwind for financial markets in Q4 2024 and 2025.
The chart below shows that in the U.S., the fiscal policy contribution to real GDP growth will become roughly neutral in the fourth quarter of 2024, and be mildly negative throughout 2025. The Brookings Institute’s projection shown in the chart assumes an extension of the provisions of the 2017 Tax Cuts and Jobs Act that are set to expire at the end of 2025, an assumption that we find most plausible. Trump has stated that if he wins, the tax cuts will of course be extended, while Harris pledges to re-distribute the fiscal burden among tax brackets. In both cases, overall tax revenues will not look very different.
Overall, the conclusions from our recent note covering the U.S. election “US Election Color Wheel: Spotting the Green in the Blue vs. Red Landscape” still hold: Harris’ approach of an “all of the above” domestic energy policy (including fracking) is unlikely to tarnish the allure of investing in regulated carbon markets. Meanwhile, sectors like engineering services will prove resilient regardless of who makes it to the White House since it’s now common lore that the U.S. needs improved infrastructure as well as more (cheap and clean) energy.
What else should thematic sustainability investors keep an eye on in the months ahead? Consumer health and a potential defensive rotation top our list.
Consumer Check- Up
Financial market pundits are ratcheting up expectations for a recession, which typically means bear market. But for the U.S. to slide into recession, it will take a much bigger crack in consumer spending.
With excess savings now largely been worked off, credit cards and other forms of consumer financing have also become more heavily tapped. So much so that lending institutions are beginning to ring a warning bell. Comments from consumer finance company Ally Financial earlier this week – and the company’s stock price reaction (-19%) – particularly struck us. The CFO articulated a view whereby borrowers have been struggling with the cost of living, and now are also faced with a deteriorating employment backdrop; late-stage loan delinquencies are rising and there is a necessity to shore up reserves.
To be sure, the Fed’s highly anticipated September interest rate cut is designed to alleviate building stressors in the consumer sector and interest rates at the long end have already declined somewhat. Nonetheless, consumers are less sanguine about their economic prospects and it is rational that this translates into a pullback in discretionary spending.
So far, 2024 has already seen a modest outperformance of consumer staples stocks relative to consumer discretionary names when looking at the overall S&P sectors. This is true even when omitting index heavyweights Tesla and Amazon from the discretionary universe. Given the discussion above, we expect that staples will continue to outperform discretionary stocks as consumers pull back spending.
Admittedly, however, sustainability concerns have not been a factor in driving the outperformance of staples: since January, SMS’ universe of consumer staples sustainability winners (primarily food companies) has only performed on par with our universe of consumer discretionary sustainability losers. Much of the disappointing result is coming from strong price appreciation of single names in our consumer discretionary short universe: despite sub-par ESG and sustainability records, cost-conscious consumers have not shied away from fast-fashion (Abercrombie & Fitch is up 67% YTD) and fast food (Wingstop and Brinker International are up 61% and 48%, respectively). Although this underscores the need for strong stock selection, as we wrote in a recent note “Consumers Bite Off More Than They Can Chew: An Outlook for the Restaurant Industry”, the current economic environment nonetheless implies less restaurants (discretionary) and more food at home (staples). We expect that the outperformance of staples will continue and stronger sustainability candidates offering good value will be propelled higher.
Defensive Rotation?
The decent performance of consumer staples recently is of course also thanks to an important rotation out of tech stocks that began this summer. We continue to believe that risks favor more air coming out of still sky-high valuations in AI-hyped stocks and it’s not just staples that will benefit. The health care sector helps form the backbone of diversified sustainability portfolios and current macro conditions are helpful for this sector.
Overall, the health care sector displays defensive characteristics much like staples; it’s hard to cut back on medications and health care procedures even when times get tougher. It is worth noting that Harris acknowledged the ravages of the fentanyl crisis in the Presidential debate and that the NOPAIN Act (Non-Opioids Prevent Addiction in the Nation Act) is a popular, bipartisan legislative effort, aiming to reduce opioid dependence by expanding access to non-opioid pain management treatments. Starting in 2025 separate Medicare reimbursement for FDA-approved non-opioid therapies will be provided, particularly in outpatient surgical settings. Pharmaceutical companies such as Pacira BioSciences (PCRX US), Indivior (INDV LN), and Vertex Pharmaceuticals (VRTX US) are developing non-opioid alternatives, positioning themselves as promising investments.
With U.S. interest rates now on a downward trajectory – approximately 200 basis points of cuts are anticipated over the next 24 months – and electoral polls indicating a tight race between Donald Trump and Kamala Harris, today’s note revisits the performance of our sustainability themes during electoral periods. We also assess the economic and policy differences between the 2020 context and today and explore opportunities for re-entry into some of our favorite investment themes.
First, we examine the performance of seventeen of SMS’ sustainable investment themes three months before, and three months after the 2020 election. Recall that interest rates were near zero during this period due to COVID-19. Some themes, such as Human Capital (which includes edtech, up 68%), Tech Infrastructure, and Transition Materials (up 45%), performed exceptionally well, while others, like Alternative Energy, somewhat underperformed (up 5%) post-election – especially we consider that the S&P 500 was up by some 10 percentage points in the three months following the election. In our view, the performance of many of our themes was driven more by market momentum and close-to-zero interest rates than by any government policies discussed during the 2020 election.
As such, there was a clear rotation in and out of several sustainable investment themes following the 2020 election. This time around, investors should also be prepared for another election-based market shift – especially if we consider that market participants already penciled in a Trump victory - and discounted several sustainability plays. Now that a Harris victory is the cards, investors could re-ignite the kind of hype in themes such as renewables and energy transition we last witnessed in 2019-20.
A second consideration is to explore how the election could alter the fundamental trajectory of U.S. policymaking, which could also impact several of our investment themes. The table below outlines our expectations for what could stay the same versus what could change following the election - and identifies potential areas for surprise.
Given the table above, we suggest four sustainable investment ideas that take into account the current U.S. political and monetary backdrop: Shorting prisons, going long on carbon, engineering firms, and renewable energy.
Short Prisons
Private prisons remain a contentious theme in the U.S., with equity prices in the sector closely tracking electoral polls. While Kamala Harris would likely aim to shut down private prisons and prolong Biden’s policy on the matter, Donald Trump would probably expand their role in the U.S. carceral system. As Harris is currently leading Trump in the polls, prison stock prices have already receded. Companies such as GEO Group (GEO US) have already profited from stricter immigration control policies, including electronic surveillance through apps, which have boosted revenues for companies in the sector. One could expect such controls to be less infringing on immigrant rights should Harris win, likely capping prison stock prices.
From a valuation perspective, prison stock prices also seem stretched when considering their 12-month trailing P/E ratios – they are trading at a 50 percent premium compared to their 2020 levels. That said, as immigration remains an important electoral theme – and in a context where private prisons increasingly rely on immigration flows as a source of revenue - we recommend taking a smaller short position on this theme while continuing to monitor polls closely.
Long Carbon
One of the starkest wedge issues between Kamala Harris and Donald Trump is their stance on the environment and carbon. Kamala Harris, known for her prosecutorial background, did not hesitate to take on Big Oil and win a settlement for the people of California over environmental damage from climate-warming fossil fuel emissions. In contrast, Donald Trump advocates for minimal, if any, environmental regulations.
This divergence in views is evident in North American regulated carbon markets. December 2024 carbon futures have recently plummeted due to 1) the prospect of Trump winning the election (especially when he was leading in polls), 2) the politicization of carbon markets (the State of Washington has put the termination of its newly created carbon market on the November 5th ballot), and 3) retail investors feeling the pressure and cashing out of their positions.
That being said, current North American carbon auction pricing dynamics are approaching the government-set floor price of $24.04, which is 25% lower than the most recent auction price of $30.24. As a reminder, the floor price is set by WCI member governments to increase by 5% plus inflation every year. For an investor with a six-year time horizon, the floor price will be equivalent to the current price in 2030, even if inflation is 0% between now and then. Investors now have the chance to buy the equivalent of a convertible bond that will pay inflation between now and 2030 with a conversion price equivalent to the current price. If the price of carbon credits rises to last spring’s peak of $44, a return of almost 50% could be achieved. For public market access to this play, investors can purchase the KCCA ETF, which has dropped by about 25 percentage points since its February 2024 peak.
Furthermore, the foundations of the North American carbon market remain strong. New York State is contemplating the creation of its own market, which could potentially merge with the Western Climate Initiative, which include the main players in the market such as California and Québec. Additionally, current electricity demand trends in North America, particularly in California, suggest that the scarcity of emission rights could return soon amid a growth in production – including from non-renewable sources. This is currently our strongest conviction for a “Kamala trade.”
Long Renewable Energy
In a recent note, we recommended re-entering the renewables sector when and if interest rates began to decline (see our note “A Second Wind: What Peak Interest Rates Mean for Renewables” March 21, 2024). Now that approximately 200 basis points of rate cuts are priced in over the next 24 months, we are somewhat surprised that the sector hasn’t yet rebounded, especially in light of recent trends in energy demand in the U.S. In that, we think that the time to re-enter the renewables space is now.
While we don’t anticipate additional government funding à la Biden IRA for the sector just yet, overweighting the sector could makes sense if you think that Kamala will make it to the White House. Companies - developers and operators - that have demonstrated strong revenue growth these past years amid higher interest rates – such as Acciona and Hannon Armstrong – could strongly reprice positively in the coming months, even if they are already trading at high P/E ratios.
Long Engineering & Construction
Given that infrastructure spending is likely to persist regardless of who wins the White House, the Engineering Services sector looks promising, especially for companies with a strong presence in the United States. We place particular emphasis on those that have developed leading sustainability practices. Many of the companies listed below have integrated sustainability as a key feature of their practice, making them a natural fit for sustainability-focused portfolios as they are the builders of infrastructure of the future.
The sector has substantially outperformed the rest of the stock market since November 2020 and, to much surprise, has even proved resilient to the current higher interest rate environment. To this end, SMS’s Green Engineering Leaders Equal-Weighted Index has outperformed both the S&P and Nasdaq by nearly 100 percentage points since Biden was elected to the White House in 2020. Given both parties’ interest in improving infrastructure, we believe this trend will continue for the foreseeable future. Companies like Stantec and Arcadis stand out in this group for their sustainability features and relatively attractive valuations.
Macro: “A Tall Order for Restaurants”
At the start of the month, U.S. Employment data sent a shock wave through financial markets. There were fewer jobs created than was expected and the unemployment rate increased to its highest level since October 2021. And just yesterday, a significant downward revision of the number of jobs created in the 12 months leading up to March 2024 was announced. This trend does not bode well for discretionary spending like restaurants, especially when interest rates remain elevated.
Although subsequent data struck a more “goldilocks” tone, we still see reasons to believe that households will curtail spending at restaurants:
- Although overall inflation fell below the 3% mark for the first time in over three years, for food prices, the cost of dining out is significantly outpacing the cost of eating at home. To be sure, restaurant food inflation can be taken as a sign that restaurants have been able to pass on higher input costs to consumer. However, as the relative cost of dining out vs dining in become stretched, we expect that more consumers will turn budget-conscious and opt for eating at home.
- The latest retail sales may have surprised to the upside, but a closer look at spend on bar and restaurants shows that spending on food away from home is starting to plateau since its post-pandemic boom (see chart below). On a monthly basis, food services and bar sales increased 0.3% while grocery store sales rose by 1% reflecting the swap to dining in as mentioned above. These observations are especially noteworthy given that retail sales data does not adjust for inflation which remains elevated for dining out. Furthermore, sales data for other discretionary areas, like leisure and apparel, were weaker compared to the previous month.
At Sustainable Market Strategies, we are more inclined to short the restaurant industry concerns over nutritional content and quality of employment. This is fitting for the current economic backdrop. However, we also remain vigilant for potential buying opportunities if value has been created. The remainder of today’s note focuses on American publicly traded restaurant companies, as there are virtually no comparable European listed options, and companies listed in Asia are further removed from U.S. economic and consumer data.
Corporate Responsibility in Restaurants: The Long and Short of It
The biggest issue with the restaurant industry is the poor nutritional value offered to customers. In our list of publicly traded American restaurant companies with over 1 billion USD in market cap, most fall into the fast-food category, also known as limited-service restaurants. Sure, everyone loves a treat and the convenience of take out, but the widespread availability of cheap, high calorie meals is problematic: the expansion of fast-food chains has long been associated with rising obesity.
Unfortunately, full-services restaurants, offering sit down meals served by wait staff, don’t fare much better on the nutrition front. Two studies from 2018 showed that meals at full-service restaurants often contain even more calories than the meals at fast-food chains. None of the companies in these two segments (limited and full service) stand out as having a more health-focused brand, we therefore do not consider them for long positions.
The last two decades saw the emergence of a third restaurant category: Fast casual. These restaurants offer the same quick convenience, often in a more upscale dining experience. Fast casual restaurants tend to have more limited menus with basic ingredients, benefitting from simplified supply chains. This category is where we see the greatest potential for long candidates. Not all fast casuals are created equal: some, but by no means all, emphasize healthier menus. We consider what they serve, average calorie content and branding (self-proclaimed mission or menu description). Our analysis identifies Sweetgreen, Chipotle and Cava as candidates for long positions given their lower in calorie and higher in vegetables menus.
According to the Sustainability Accounting Standards Board (SASB), another material consideration for the restaurant industry is their role as employers. Restaurants are major employers in the U.S., but these jobs tend to offer low pay, few benefits and poor working conditions. None of the companies we reviewed had a CSRHub Employment Score rank within the top 20%. Though none qualify as high-quality employers, we deem companies with scores below the 40th percentile as particularly underperforming. The companies are ordered by their Employment score rank in the table below.
Finally, we assess energy, waste and water metrics (also key topics identified by SASB). The extensive number of restaurant locations makes for a significant environmental footprint. Food safety and Supply Chain Management are also flagged as key issues by SASB. Food safety is difficult to assess beyond health records and past controversies. For supply chain management, we give a leg up to the fast casual restaurants given their simplified menus. The table below presents our findings on the three categories of restaurants.
For the fast casual segment, we retain only Chipotle on the long side. Despite better nutrition in their menus, Cava Group and Sweetgreen (whose labor score is notable) do not have sufficient disclosures to retain as long opportunities. Wingstop is kept as a short candidate given its weaker labor score and lack of reporting on environmental factors. Recall that limited and full-service restaurants are only considered from the short angle given their poor nutritional value. Three shorts are identified in the full-service segment: Darden Restaurants, Texas Roadhouse and Bloomin Brands; and two in the limited-service segment: Domino’s Pizza and Krispy Kreme. These companies are identified as short candidates due to their poor labor scores and weak disclosures.
Various Business Models Drive Diverging Stock Results
Since the pandemic reopening, fast casual restaurants stock prices are the only segment that have outperformed the SP500. The performance or full-service restaurants is relatively flat and limited-service restaurants have seen price declines.
This can be attributed to the different business model characteristics of each of the restaurant segments. Fast casual and full-service restaurants have higher price points and therefore tend to have higher-income patrons that are better able to weather the rising inflation over this period. Up until 2024, the performance of these two segments was mostly aligned. But fast casual has two advantages over full service: health (higher quality menus) and convenience. Customers of these restaurants are seeking the convenience of a fast-food place but willing to pay more for a better quality or more specialized menu.
Most of the short candidates we identified have seen sales growth decline in the first half of 2024 compared to last year. Full-service restaurants have seen sales growth reduce the most (see chart below). Wingstop, in the fast casual segment, has also had waning sales growth, but still remains well above restaurants in the other categories (though this cannot be attributed to customers seeking healthier options and is likelier more the result of expansion). Domino’s is the exception, and may be explained by consumers trading down from fast casual or other more expensive pizza chains. Within the fast-food category, the last two quarters saw sales growth decline for both Starbucks (-0.6%) and Papa John’s (-1.3%) while it remained positive - around 7% - for Krispy Kreme and Domino’s.
In the limited-service (fast food) category, restaurants that are able to offer the best deals will be favored by consumers. With their higher margins, fast food giants like McDonald’s (33% net margin) and Yum! (owner of Taco Bell, KFC and Pizza Hut, net margin of 23%) will have the greatest capacity to offer discounts, cutting prices on some items while maintaining positive margins.
Still, if rates remain elevated and unemployment continues to rise, we expect a further decline across the board for restaurants. It is noteworthy that Krispy Kreme, Domino’s and Wingstop have the highest betas. Chipotle, a long candidate (though too richly valued today), also has a relatively higher beta.
The investment community usually has strong views about its role in solving environmental and social issues. Ask any investment professional how they approach the climate crisis, and they will enthusiastically discuss their investments in renewables and other clean technology disruptive strategies. Now ask them about their strategy to address the opioid crisis. In our experience, the opioid epidemic is one of the most critical societal issues that remains largely ignored by the financial community.
Healthcare is often perceived as a straightforward sustainability or impact investment due to its inherent focus on improving lives and promoting well-being. However, the sector is not devoid of controversies and egregious behaviors that can undermine its positive impact. Our previous research on insulin prices (see Basic Instinct: The Insulin Profit Machine, September 22, 2022) highlighted significant ethical concerns, demonstrating how certain practices can lead to affordability issues and hinder access to essential medications. For investors, it is crucial to go beyond the surface and conduct thorough due diligence to identify and mitigate such risks.
In this week’s note, we will explore the financial implications of the opioid crisis affecting millions in the United States and beyond.
The Context of a Crisis
While the opioid crisis is a global issue, the United States is particularly affected by this epidemic.
Unfortunately, the opioid crisis in the United States continues to escalate, with the number of deaths increasing year after year. Despite ongoing efforts to combat the epidemic, the situation remains dire and shows no signs of improvement.
Opioids have been the leading cause of death for individuals aged 18 to 45 since 2019, claiming 200 American lives daily. This epidemic severely impacts the American economy, with estimates suggesting it accounts for 43% of the decline in men’s labor force participation and 25% for women. States with lower median incomes and higher unemployment rates, such as West Virginia, Kentucky, and Alabama, have the highest opioid dispensing rates, highlighting a strong link between economic despair and opioid dependency.
US politicians on both sides have shown a desire to connect more closely with rural America, so it is not surprising to see “opioid epidemic” being increasingly mentioned in their respective speeches.
In late 2022, a significant demonstration of bipartisanship occurred when congressmen from both parties approved the NOPAIN Act (Non-Opioids Prevent Addiction in the Nation Act). This legislation aims to reduce reliance on opioid prescriptions by expanding access to non-opioid pain management treatments. Starting in 2025 separate Medicare reimbursement for FDA-approved non-opioid therapies will be provided, particularly in outpatient surgical settings. This legislative effort underscores a broader recognition that addressing the opioid crisis requires comprehensive strategies, including holding various sectors accountable.
The Offenders
Although a large part of the blame must go to pharmaceutical companies that designed, manufactured, and promoted these products, other parts of the healthcare sector, such as distributors, retailers, pharmacies, and insurers, also share in the responsibility. The legal troubles for a suite of healthcare companies began a decade ago when state and municipal governments across the United States launched thousands of investigations. The specific crimes and subsequent settlement amounts varied depending on their roles in the opioid crisis.
For many, the most notorious offender in the opioid crisis is Purdue Pharma and its owners, the Sackler family. They will forever be remembered as the creators of OxyContin, a drug that was deceptively marketed as having a low risk of addiction despite its potent similarity to heroin. Purdue Pharma ultimately declared bankruptcy but initially agreed to pay $6 billion for its pivotal role in igniting the opioid epidemic. Originally, the settlement shielded the Sackler family from future civil claims though they had withdrawn billions from the company before the bankruptcy. However, in a surprising turn of events last month, the Supreme Court rejected this part of the settlement, potentially reopening the door to thousands of lawsuits against the Sackler family.
More pertinent for current equity investors is what role publicly-listed healthcare companies played and how they responded to accusations. Investors' decisions to include or exclude these companies from their portfolios will vary based on individual tolerance and justification.
The Opioid Cartel: Who is Responsible for What
For sustainability-minded investors, it is crucial to seek assurance that companies will behave differently if a similar situation arises. The opioid crisis highlighted failures across the entire healthcare supply chain:
- Drug developers (Purdue, J&J, Allergan, Teva) made false claims about addiction risks and incentivized doctors to prescribe larger doses to more patients through perverse incentive programs.
- Drug distributors (McKesson, Cardinal Health, and AmerisourceBergen/Cencora) failed to monitor and report unusually large or suspicious orders of opioids, violating the Controlled Substances Act.
- Retailers like CVS demonstrated insufficient oversight and controls to detect and prevent the abuse and diversion of opioids for illegal use.
The failures on multiple levels underscore the importance of having accountability and robust ethical practices within the healthcare industry to prevent future crises.
The "Responsible Investment Theory" suggests that companies engaged in controversial behaviors should suffer financial or reputational damage. However, with a few exceptions such as the bankruptcies of Purdue Pharma, Insys Therapeutics, and Mallinckrodt, many larger players have largely weathered the storm. Companies like Johnson & Johnson and CVS have faced the opioid settlements as one of many challenges in recent years, indicating that the impact on their financial health and reputations has been somewhat limited compared to their overall market presence and diversified operations.
Looking ahead: the investment opportunity
The upcoming implementation of the NOPAIN Act could mark a significant inflection point for investors seeking to address the opioid crisis through strategic capital allocation. By boosting non-opioid alternatives, the Act opens new investment avenues for impact-minded investors.
The investment opportunity falls into two main categories: companies providing pharmaceutical solutions to current opioid dependence, and companies developing non-opioid alternatives for pain management.
For the first category, we focus on companies offering overdose reversal medications like naloxone hydrochloride nasal sprays, and other treatments to prevent relapse in opioid-dependent patients:
- Emergent BioSolutions (EBS US): This small-cap company manufactures Narcan (naloxone), a widely used opioid overdose reversal medication crucial in saving lives during opioid overdose emergencies.
- Indivior (INDV LN): Indivior is actively developing non-opioid alternatives for pain management, including INDV-2000, an investigational non-opioid treatment for individuals with opioid use disorder (OUD).
- Alkermes (ALKS US): Alkermes produces Vivitrol, a medication used to prevent relapse in patients with opioid dependence by blocking opioid receptors in the brain, helping individuals maintain abstinence from opioids.
In the realm of developing alternative non-opioid pain management medications, one might expect a crowded field given the significant market potential for effective pain relief that avoids addiction risks. However, pain management research is notoriously challenging and often leads to dead ends. After years of arduous clinical trials and numerous unsuccessful attempts by Big Pharma to discover new mechanisms for pain treatment, there is finally a glimmer of hope.
In late July, the FDA granted Vertex Pharmaceuticals (VRTX US) Priority Review for its New Drug Application for suzetrigine, an investigational oral non-opioid treatment for moderate to severe acute pain. The FDA’s decision is expected by January 30, 2025. If approved, suzetrigine could become the first new class of drug approved for acute pain in over 20 years! Unlike opioid-based painkillers, suzetrigine treats pain without entering the brain, thus avoiding the addiction potential that opioids present. This new class of medication will undoubtedly be more expensive than traditional opioid drugs, but the NOPAIN Act addresses this issue by providing higher reimbursement rates for non-opioid drugs.
Another company poised to benefit significantly from the implementation of the NOPAIN Act is Pacira BioSciences (PCRX US). Pacira produces EXPAREL®, a non-opioid local analgesic used for postsurgical pain management. The NOPAIN Act's reimbursement changes are expected to significantly increase the utilization of EXPAREL® in surgical settings, enhancing its market penetration and impact.
These developments underscore the recent breakthroughs creating promising opportunities in non-opioid pain management. These drugs present substantial potential for positive impacts on both public health and investment returns. Screening for valuation and market capitalization, a strategic combination of Vertex Pharmaceuticals (VRTX US), Pacira BioSciences (PCRX US), and Indivior (INDV LN) looks like an attractive investment approach to capitalize on the implementation of the NOPAIN Act in 2025.
Investing in these companies not only aligns with emerging healthcare trends but also supports the transition towards safer, non-addictive pain management solutions.
Sustainable Market Strategies’ research team is an eclectic mix of analysts and strategists that are not afraid to debate contentious issues. One particularly contentious topic is gender; we note that the recent past has been bi-polar for gender issues. At one extreme, reproductive rights in the U.S. have been severely curtailed, leading to questions about the overall state of women’s rights. At the other extreme, the proliferation of women’s professional sports and a marked uptick in capital allocation to female health care suggest that some industries are becoming more gender balanced and are in fact providing potentially exciting investment opportunities.
What follows in today’s Note is a summary position of our ongoing, internal debate regarding various gender issues (by no means a complete list) that have the potential to impact investment decisions.
True or False: The gender pay gap has deleterious effects on economic growth.
True. It’s no great secret that women earn less than men. The reasons behind this are many and range from blatant discrimination, sub-optimal parental benefits and structures and the preponderance of pink-collar industries, e.g. nursing and education, to be less lucrative than blue collar jobs (despite often requiring more advanced education). In the U.S., the gender pay gap has not budged in the past twenty years, though many other countries have made substantial progress.
What would it mean for economic growth if the gender pay gap were to close? A lot. In 2023, Moody’s estimated that closing the gender gap in OECD countries would raise global economic activity by approximately 7%, or about $7 trillion USD.
Amazingly, the Moody’s report came up with this estimate solely based on the assumption that women could actually access the jobs that matched their education level. In most OECD countries and major emerging markets, the number of women aged 25 to 64 with a master’s degree or equivalent exceeds that of men.
And yet, as the chart below highlights, the proportion of women in senior and middle management positions is paltry compared to men. The implication is that the return on investment of education is sub-optimal and the underutilisation of women’s skills and time, causes an economic loss at both the individual and macroeconomic levels.
True or False: Women-run companies produce better financial returns
False: being female isn’t a superpower, but diversity is. The question of whether women-run companies produce better financial returns has garnered significant attention and research. We tackled this subject in a previous note in 2019 (“Gender Diversity: What’s the data telling us?”, August 8, 2019), which highlighted the difficulty of finding data points linking financial performance and gender diversity.
As discussed in the previous section, women are still far outnumbered in senior roles. They make up less than 10% of CEOs of S&P500 companies (see chart below).
In 2023 however, women CEOs had a breakthrough, finally outnumbering CEOs named John (!) as more women are taking the top job. This milestone reflects broader trends suggesting growing recognition that diversity in leadership positions is advantageous.
Indeed, research from McKinsey shows that diverse boards and executive teams are positively correlated with better non-financial performance, including higher social and environmental impact scores. Specifically, companies with increased gender diversity in leadership show improved performance in community, workforce, and environmental scores. The following chart highlights how a 10% increase in women’s representation on leadership teams correlates with higher scores across various impact metrics.
While women-led companies often see strong financial returns, the true driver of success is the diversity they bring—encompassing varied perspectives and cognitive multiplicity.
True or False: Women sports teams are having a breakout moment and it matters for investors.
True. Fueled by shakeups in media consumption, women’s professional sports are experiencing significant growth and popularity.
Recent years have shown how more diverse content can be a driver of success. Netflix’s business model is a key example: more varied programming has helped to uncover audiences previously neglected by traditional content creators and video streaming facilitates access to this content. Just like Netflix did for film and television programs, the proliferation of women’s teams boosts diversity in sports entertainment, therefore drawing in a wider audience. Social media has further bolstered the impact of these changes by delivering tailored content to target likely fans. And female athletes who previously faced a coverage gap compared to their male counterparts can now connect directly with supporters via social media platforms.
The result has been a spike in popularity for women’s sports. Momentum from a record setting 2023 has carried into this year. The Professional Women’s Hockey League (PWHL) kicked off its inaugural season. Initially scheduled in smaller arenas, sold out venues prompted organizers to move some games to larger capacity locations including the largest hockey arena in North America: the Bell Centre (which also sold out). At just the midpoint of its 11th season, the National Women’s Soccer League (NWSL) attendance had increased 42% over last year’s record numbers and merchandise sales were up a staggering 290%! The Kansas City Current became the first NWSL team to have their own dedicated home stadium. Financed with support from JP Morgan, the ownership brings more control and choice, helping to unlock new revenue streams and drive growth. It is seen as a template for other teams to follow. And in basketball, (if you hadn’t heard already), the women’s march madness final drew in nearly 4 million more viewers than the men’s championship game. This wave of enthusiasm is expected to have a ripple effect on the WNBA as top college players enter the professional league.
These previously unmeasured metrics (thanks to a lack of coverage for women’s sports) suggest significant growth prospects. A report by Deloitte released at the end of last year projects women’s sports to earn over $1 billion USD in 2024, some 300% higher than their forecast from 2021, underscoring the immense upside potential. Though past iterations of women’s leagues have folded, today’s teams are supported by a changed media landscape and a flywheel effect in full swing (see diagram below). With sponsors and broadcasters already taking notice, this self-reinforcing cycle suggests the momentum behind women’s sports is here to stay. As market value continues to rise, there is the potential for valuation convergence with men’s sports.

Investment opportunities in women's sports primarily lie in the private equity space, as there are few pure plays in publicly traded companies. However, as viewership increases, so does the potential for merchandise and sponsorship deals, leading to revenue growth for broadcasters, stadiums, concessions and jersey sales. Though the companies in these segments predominately serve men’s teams (at least historically), their allyship is a key step forward.
True or False: Women have been shortchanged in health care and an investment catch-up phase is likely.
True. Health care is another area where a prevailing data gap has adversely affected women. Historically, women have been consistently underrepresented in medical research. There are issues of overreliance on male mice for preclinical studies, an insufficient number of women at the trial stage and failure to account for sex-based differences in outcomes (all of which are well documented in Criado-Perez’s book Invisible Women). Furthermore, when it comes to female-specific ailments, research is extremely underfunded. A 2022 McKinsey report showed that, excluding women’s cancers, only 1% of health care research spending is focused on female-specific conditions (women’s cancers receive 4%). As recently as 2015, studies on erectile dysfunction (affecting 19% of the male population) outnumbered studies on premenstrual syndrome (affecting 90% of women) by three times!
Signs of a catch-up are beginning to emerge. This year alone, the Global Alliance for Women’s Health was launched at the World Economic forum in Davos; in March, Biden signed an executive order prioritizing women's health research and a significant portion of Melinda French Gates’ announced donation of $1 billion towards women’s causes is specifically tagged for health projects. Such initiatives should provide momentum to ongoing efforts, help to spur further action and encourage greater investment in women’s health research.
As this wall of money floods the sector, both start-ups and existing companies that focus on treating female-specific maladies will benefit. Operating in a more nascent industry, women’s health companies are at earlier phases of development. These could be prime candidates for acquisition by larger, more established health care players. There are a number of female-focused companies under $1 billion USD in market cap. Alternatively, investors can study how the major pharmaceutical companies are incorporating women’s health into their growth strategies. Are their acquisitions and R&D spend being directed to women’s health solutions?
Two of the largest publicly traded companies in women’s health are Hologic (market capitalization of $17 billion USD) and Organon ($5 billion USD). Hologic operates as a health care equipment company specializing in diagnostics, focusing on products such as mammography and breast biopsy systems as well as skeletal health and gynecological surgical devices. Like other health care companies, Hologic experienced outsized sales during the pandemic from its Covid diagnostics test product, but growth in its more female-centric segments remained strong in 2023. Organon is in the pharmaceuticals sector, concentrating on reproductive health and hormone therapy. Its stock price has struggled somewhat since the spinoff from Merck in 2021 but is rebounding in this first half of 2024. In terms of valuation, Organon comes at a much lower valuation (FWD P/E 4.5) than Hologic (FWD P/E 17.1) and the SP500 Healthcare sector (FWD P/E 19.1).
True or False: The Pink Tax Is real and presents a business risk to some consumer discretionary companies if it were “abolished”.
True, but it is an overstated risk. The pink tax refers to the tendency for products marketed specifically toward women to be more expensive than those marketed toward men and the phenomenon is often attributed to gender-based price discrimination. If it exists, the ramifications are quite obvious. First, from a consumer perspective, it would mean that women – who already suffer from an income and pension gap – have a higher cost of living than men, all else equal. Second, it means that companies using this strategy can generate higher profit margins based on discriminatory pricing and would be at risk of margin squeeze if/when the practice were to be abolished (either via consumer or shareholder pressure or a regulatory change).
Much of the pink tax attention has focused on personal care products whereby gender segmentation is ubiquitous, as more than 80% of products in this category are gendered. Various studies show pricing discrepancies exist, although some argue it is for valid reasons, e.g. product composition, women’s higher willingness to pay for quality. Studies in Argentina, the U.S., the U.K. and Canada all show evidence of this practice with the price gap of various consumer goods products averaging between 5 and 20%.
Attempts to do anything about gender pricing have been mostly futile from a regulatory perspective. There are two U.S. states (NY and California) that explicitly outlaw a “pink tax”. At the U.S. federal level, the Pink Tax Repeal Act, has been introduced several times in different iterations since 2016, most recently in 2021, but has never passed. We are not aware of regulation regarding the pink tax elsewhere in the world.
In any case, personal care product companies do not view gendered pricing as a problem or risk to their business. Using Bloomberg’s “docusearch” tool, we find only a handful of companies addressing the pink tax in any sort of way. In the personal care segment, only CVS Health (CVS), Boxed and Billie (the latter two are private companies) are flagged as addressing the issue.
The bottom line is that for investors, absent meaningful consumer pressure, there is low risk that a meaningful change in pricing strategy would negatively impact profits (we did not find any companies that divulge profit margins disaggregated by gendered sales).
True or False: Women’s rights are regressing and it matters for capital markets
False. Media coverage on the threat to abortion access in the United States is surely overshadowing progress in gender equality that has been achieved in recent decades (at least in the developed world). To be sure, the U.S. is not alone. In Italy, the rise of right-wing political forces has led to increased opposition to reproductive rights and other gender equality measures. And we note that there is a correlation between far-right uprisings and regression of women’s reproductive rights.
The threat to reproductive rights should absolutely be taken seriously, but there have nonetheless been substantial progress on several women’s rights issues, including reproductive rights. Most recently, France became the first country to enshrine women’s right to abortion in their constitution.
Though women still hold a minority of positions in government, there has been some progress in this area, as shown in the chart below. Mexico serves as a powerful example of the effectiveness of representation: five years ago, a constitutional reform required equal numbers of male and female candidates for government positions. In 2024, both of the country’s top political parties chose female candidates as their presidential nominees!
Women are also making gains in the boardroom as discussed in the previous sections. And despite a persistent wage gap, data from the United States shows that women who entered the workforce in 1983 have seen their lifetime earnings increase 33% in real terms compared to the previous generation (for the same period, men can expect to earn 10% less).
Still, according to the World Economic Forum’s report on the global gender gap, it will take 134 years for women to reach full parity globally at the current rate of progress. Given that gender parity would, as highlighted above, significantly increase economic output and prosperity, there is a massive incentive to more rapidly close this gap. Investing in areas that promote gender equality is just one way to contribute to reducing this disparity, and the widening opportunity set shows increasing promise.
Current Healthcare Challenges
Healthcare systems globally are facing unprecedented challenges, such as overwhelming patient loads, strained resources, and logistical hurdles, all of which were starkly highlighted during the COVID-19 pandemic. The main concerns worldwide about healthcare systems are reflected in the chart below:
AI's Emerging Role in Healthcare
As discussed in our recent notes ("Waste & Water, Not Your Typical AI Investments," April 18, 2024, and "From Gridlock to Grid Smart: AI’s Role in Electricity Efficiency," April 4, 2024), AI has the potential to disrupt many themes important to sustainability-minded investors. This week, we focus on AI’s applications in healthcare.
Artificial Intelligence offers potential solutions to some of these issues. The exponential growth of healthcare data, advancements in AI algorithms, and the potential for improved diagnostic accuracy and treatment outcomes are driving AI adoption in healthcare. The surge in healthcare data is fueled by electronic health records (EHRs), wearable devices, and genomic sequencing. Advances in AI, especially machine learning and deep learning, enhance the ability to analyze complex medical data and provide actionable insights. Moreover, the medical industry continuously strives for more accurate and personalized diagnostics and treatments to improve patient outcomes and operational efficiency, driven by demographic changes and technological advancements.
Relative to the healthcare sector’s weight in the index, its share of AI mentions lags Technology, Financials and Industrials.
However, there is evidence of that the potential for AI usage is gradually growing within the sector, as indicated by the rapid increase in AI mentions in the earnings calls of healthcare companies, especially over the past two quarters (see chart below).
Research by The Economist suggests that more than 50% of health AI vendors were established since 2017, indicating a rapid expansion and interest in this field. However, this advancement is accompanied by significant concerns ranging from ethics, safety and regulatory challenges. These will need to be addressed to ensure the responsible and equitable deployment of AI technologies.
Ethical Considerations in AI Adoption
One major concern is bias. Bias in AI within healthcare risks exacerbating existing health disparities. When AI systems are trained on data that lack diversity or are otherwise unrepresentative of the broad population, they can produce biased outcomes that disproportionately affect marginalized groups. Some studies have shown that healthcare algorithms often underperform for racial and ethnic minorities compared to white populations, leading to unequal treatment and care recommendations.
The following chart illustrates the complex perspectives of Americans regarding racial and ethnic bias in health and medicine issues. The data reveals that 64% of Black adults identify racial and ethnic bias as a major problem in healthcare, compared to 27% of White adults.
Addressing this issue requires a multi-faceted approach. Healthcare companies need to ensure that their AI systems are developed with diverse, representative datasets. Accessing large, diverse sets of medical data is hard. Training health-oriented AI requires large volumes of high-quality data. Many companies generate this data themselves as part of their drug development programs, ensuring it is comprehensive by including data from various demographic groups and continuously updating datasets to reflect the current population.
Moreover, transparency in the development and deployment of AI models is crucial. This involves making the data sources, decision-making processes, and potential biases of these models clear to both users and regulatory bodies. Furthermore, involving stakeholders from diverse backgrounds, including patients and community representatives, throughout the AI development lifecycle can help identify and mitigate potential biases early on.
Beyond the issue of bias, several other significant concerns arise with the integration of AI in healthcare. The following list is derived from a 2021 KPMG study, where Americans were surveyed about their concerns regarding AI in healthcare:
- Safety Issues: Ensuring rigorous testing and validation of AI systems is crucial, as evidenced by a 2021 study in Nature Medicine where an AI system misdiagnosed pneumonia, potentially delaying treatments. Machine errors are less acceptable than doctors' errors, similar to the scrutiny faced by autonomous cars compared to human drivers.
- Privacy and Security: Healthcare data is a prime target for cyberattacks, as seen in the 2017 WannaCry ransomware attack on the UK's NHS, underscoring the need for robust cybersecurity measures.
- Malicious Takeover: AI systems could be hijacked by malicious actors, leading to consequences like altered patient records or disrupted services.
- Loss of Personal Interaction: Numerous studies stress the importance of human elements in patient care, which AI cannot fully replicate. Although interestingly, people seem to find it easier to disclose their intimate history to a chatbot than to a nurse, highlighting the potential of AI to nevertheless facilitate sensitive healthcare conversations.
- Economic Inequality: Dominance by large tech companies in AI healthcare could stifle innovation and marginalize smaller players, exacerbating economic inequalities.
- Job Displacement: Although a concern, integration of AI should complement, not replace, healthcare workers, as highlighted in studies emphasizing reskilling opportunities to ensure job transformation rather than elimination.
Navigating AI Regulations
Despite these issues, regulation for AI in healthcare has begun, but likely has much further to go to ensure that the above concerns are appropriately safeguarded against. As of 2024, several key developments indicate a trend towards more robust regulatory frameworks:
There is currently little comprehensive regulation surrounding AI in healthcare, but we expect this to become crucial over time. There is a global consensus on the need for regulation to keep pace with AI advancements. These elements underscore the necessity for a balanced approach to AI adoption in healthcare, ensuring technological advancements are ethically sound and beneficial to patient well-being. The companies that will be best positioned for the future are those that proactively engage with regulators to shape effective and fair AI policies, ensuring compliance with emerging standards and participating in ongoing dialogues about regulatory developments.
Investment Opportunities in AI-Driven Healthcare
The healthcare sector holds the most promise for positive disruption from AI, showing potential to outperform humans in tasks like disease diagnosis from medical images. However, the risk of amplifying existing biases and regulatory uncertainty impacts the risk/reward profile for AI investments. Thus, healthcare companies that effectively integrate AI while addressing these ethical concerns and navigating regulatory changes will emerge as winners.
To identify these companies, we take the following points into account:
- Certain healthcare subsectors are more likely to be impacted by AI than others. In a previous note on healthcare ("High Impact: Surviving a Recession With Care," June 2, 2022), we categorized healthcare subsectors within our two sub-themes:
#1 - Healthcare Innovation: Advances in science are enabling research on medical treatments and therapies. In addition, technological innovation is improving outcomes for patients with a range of diseases. This progress helps to extend life expectancy and improve quality of life for individuals suffering from illness.
This subtheme comprises the subsectors Research, Solutions to Critical Diseases and Health Technologies.
#2 - Access to Healthcare: Rising demand for quality healthcare from developing nations and aging populations of the developed world will require an expansion of existing products and services. Companies that leverage improved productivity to provide diagnostics, medication, products for wellbeing and patient care services will contribute to improving healthcare access.
This subtheme comprises Diagnostics, Drug Production, Wellness, Health Insurance Providers, Care Facilities & Services, Healthcare Distributors & Services and Equipment & Devices.
While AI can support improvements in all of these subsectors, we highlight in the table below the areas where we think AI will have the greatest impact.
These are the 5 subsectors stand out as most likely to benefit and/or be disrupted from AI: Research, Solutions to Critical Diseases, Health Technologies, Diagnostics, and Equipment & Devices.
- To find the best companies within these subsectors that fully leverage AI, we conduct the following steps:
- Identified healthcare companies with the most AI mentions in their transcripts over the past five years, selecting the top 100 and filtering out companies with a market capitalization under US$ 1 billion.
- Analyzed the remaining 60 companies by subsector, keeping only those in the five subsectors poised to benefit the most from AI, narrowing it down to 50 companies.
- Evaluated operational performance (ESG) and controversies, giving preference to companies free from controversy and scoring highly on environmental, social, and governance factors using CSRHub scores, reducing the list to 20 companies.
- Conducted deeper research on AI integration in product/service development, selecting 15 companies that have well-integrated AI in their offerings and/or plans.
The curated list of companies is in the table below.
These companies, across the subsectors of Diagnostics, Research, Solutions to Critical Diseases, Health Technologies, and Equipment & Devices, are at the forefront of leveraging AI in healthcare. They exhibit high operational performance, minimal controversy, and robust AI integration in their product development. As such, they should be considered as an entry point to gaining exposure to healthcare companies that are leveraging AI.
On September 10, 2020, around the first time when an ounce of gold traded at 2,000, we wrote a note: “Finding a place for gold in an ESG portfolio” whereby we identified sustainable companies involved in gold recycling and mining equipment. While the price of gold has traded sideways for the last three years, with the recent gold breakout to new all-time highs, we are revisiting the topic.
Gold is a scarce commodity. A cube of gold
with an edge measuring only 22 m would contain all the gold that has ever been mined! Other than its distinctive color, gold has attractive chemical properties: it is inert (does not corrode or tarnish), highly malleable and ductile (it can be stretched very thin), has high conductivity (electricity and heat) and is nontoxic (compatible with humans in medical devices or dental work).
What Is Gold Used For?
Due to the above properties, gold has been used as a medium of exchange and store of value (currency), in art (jewelry, decoration, craftmanship) and in technology (telecom, electronics, aerospace, medical devices, dentistry).
Despite having other useful applications, the main sources of demand for gold are jewelry and finance.
The image below, from the World Gold Council, shows the interaction between annual supply and demand for gold over the last 10 years. Gold supply has come mainly from new mining (75%) with the remainder sourced from recycling (25%). It is worth noting that the average annual amount devoted to functional use in technology (8%: 329 tonnes) is lower than the supply from recycling (25%: 1,172 tonnes). In other words, the quantity of gold needed for functional applications could be entirely derived from recycling.

What Are the Factors Determining the Price of Gold?
Let’s look at the supply and demand picture:
Supply: there is not a lot of gold left to mine, according to the World Gold Council, approximately 80% of identified gold reserves have already been mined leaving just 20% of tougher to access reserves, where the concentration of gold is lower. Meanwhile, recycling could bring a lot of existing gold back towards more useful endeavours. The chart below shows the main cost differences between mining and recycling. In mining, costs are associated with exploration, geology, and mining methods. Recycling involves expenses related to collection, sorting, and processing. There are other economic factors that determine the marginal cost of gold like interest rates, currency and inflation. Even with the price of gold at its historical high, gold supply is expected to experience only modest growth over the next decade given declining ore grade, higher extraction costs and stricter environmental regulations.
Demand: Gold experiences demand from various sectors, with jewelry, industry, financial products, and central banks are the primary sources.
- Jewelry: Gold holds cultural significance and serves as a symbol of wealth and fashion.
- Industry: In electronics and renewable energy, gold is prized for its conductivity and corrosion resistance. Medical devices like pacemakers, implants and electrodes utilize gold for its biocompatibility and inertness. Aerospace applications such as satellites benefit from gold's ability to reflect infrared radiation and protect from heat. Gold nanoparticles are used in chemical processes, while the telecom and auto industries also rely on gold for various applications.
- Financial Products: Gold is often sought after as an investment safe haven during times of economic uncertainty and also serves as a hedge against inflation. It is also considered as a form of currency, functioning as a medium of exchange, store of value, and unit of fungibility. Exchange-traded funds (ETFs), futures contracts, certificates, structured products, and gold bars offer investors ways to access the gold market.
- Central Banks: Significant amounts of gold are held by central banks as part of their reserves. They view it as a means of portfolio diversification that provides stability amidst economic fluctuations. Gold acts as a store of value, a reference point for currency valuation, and a hedge against inflation and currency devaluation.
While new supply of gold is expected to be limited, demand could increase at a faster pace from greater jewelry demand and increased industrial use. Financial product demand is a wild card; the advent of Bitcoin ETFs has taken financial flows that would normally have gone to gold (even though the gold price increased in 2023, physical gold ETF saw outflows). The most promising source of demand lies in central bank reserves that are reacting to the confiscation of Russian assets. The chart below highlights that for central banks surveyed, they expect the portion of gold in their reserves to increase (63% expect it will increase compared to 9% that believe it will decrease from the current 15%).
How to Gain Exposure to Gold?
Since the price of gold broke out to all-time highs, should a sustainable investor gain exposure through gold miners, gold royalties, gold recyclers or some form of gold bullion ownership?
Gold Miners:
The practices of gold miners have improved significantly over the years, especially for the larger firms, but many issues still exist. From an environmental standpoint, deforestation, water and air pollution, soil degradation and energy needs are all major concerns. From a social standpoint, human rights violations, health and safety, and other issues such as worker displacement, labor exploitation, and cultural disruption are worrisome. Finally, in terms of governance, challenges include corruption, lack of transparency, weak regulations, and the abuse of land and indigenous rights.
For all of these reasons, it is difficult to find long investment candidates in the mining sector from a sustainability perspective. We find it much easier to find companies to potentially short sell. Gold miners are levered to the price of gold because they have fixed costs and benefit disproportionately from higher prices. Moreover, the value of their reserves increases with the price of gold. As a result, their beta to the underlying global gold price is generally much higher than one.
Gold Royalties:
The role of royalty companies is to provide upfront financing to support initial mining costs in exchange for a percentage of the revenue generated from the sale of gold. They are exposed to the same issues as miners: instead of being the operator, they finance gold mining activities. Royalties have a lower gold beta than miners because they have lower fixed costs.
Gold Recyclers:
Considering the environmental and social damage from gold extraction, recycling offers a more sustainable option. Gold can be recycled without losing its purity, it is much less energy intensive to recycle and recycling avoids the bulk of the environmental and social risks highlighted above. Recyclers have an even lower beta to gold than royalties (less than 1).
Gold Bullion:
The sustainability argument for gold bullion is that it has already been mined. This is a weak argument in our opinion because gold mining is hard on the environment and society but some investment products, like Royal Mint’s Responsibly Sourced Physical Gold ETC, try to improve the sustainability of gold bullion by having a high percentage of recycled gold. Holding gold bullion or investment products linked to gold is not as damaging as miners or royalties, but to us, recyclers are still the most sustainable.
Which Companies Caught Our Attention?
The table below highlights gold miners with weak ESG scores versus recyclers with strong ESG scores, using CSRHub data. Barrick, B2B, Anglo and Kirkland Lake stand out as strong potential gold miner short candidates, while Sims, Umicore, Are Holdings and Johnson Matthey are potential long recyclers.
Next, from a financial perspective, the table below highlights a similarity in revenue growth over the past five years for both miners and recyclers. Valuation remains attractive for both groups, though it is worth noting that miners currently exhibit more favorable profit margins than recyclers. However, as highlighted above, 80% of identified reserves have already been mined. Given that the remaining 20% will be harder to access and yield lower concentrations of gold, miners will need to inject significant capital to explore and increase production. This will inevitably be reflected in higher capital expenditures and interest costs, thereby impacting the overall profitability of mining companies.
How Has the Gold Complex Behaved Recently?
The chart below shows an index of the four miners compared to an index of the four recyclers and the price of gold. Even if the price of gold has increased steadily since the beginning of the decade, gold miners and recyclers have struggled.
How to Position?
The resilience of the price of gold to much higher interest rates, falling inflation and reduced financial market volatility has been surprising. As we discussed earlier, physical gold ETFs saw outflows in 2023 but the main reason for gold’s resilience lies in increased central bank demand. As we have shown, most central banks expect to continue to accumulate gold in the next 5 years. Recyclers that have not yet followed the price of bullion higher should be the investment of choice for sustainable investors looking for gold exposure.
The share of consumers’ budgets dedicated to spending on food has made new multi-decade highs; in the U.S., households have not spent this much of their income on food since the 1980s. Is the long era of cheap and plentiful food behind us? We think so.
Although cyclical forces such as a tight labor market are also contributing to higher food prices, much of the increase in food costs are due to the headwinds to agricultural productivity from climate change, biodiversity loss and other environmental and social factors at a time when the global population is still growing. Indeed, these headwinds are affecting a multitude of food supply chains. Work at Ceres reveals that within each of the eight major food commodity supply chains, there exists at least one environmental or social factor considered a ‘high’ risk. This includes factors that pose threats to food production itself, as well as instances where food production contributes to environmental and social harm.
These risks are not simply theoretical and/or something to consider in the future. Take cocoa for example; West Africa produces most of the world’s cocoa, but two years of hot and dry weather have severely impacted crops; both current yields and the viability of farming in the future are at risk. U.S. cocoa futures reached a nearly fifty-year high in February!
From an environmental perspective, no food industry is more problematic than beef. Risks are rated as “high” or “medium” across all major environmental and social factors according to Ceres.
If the status quo prevails, it is likely to lead to levels of price inflation that can not be fully borne by the consumer. Put simply, industry profit margins are at risk from the environmental and social factors in the table above. In today’s note, we analyze the food supply chain of beef and cocoa. We explore how investors can both protect their capital and improve environmental and social outcomes.
What’s The Beef About Beef
The U.S. and Brazil are the largest producers of beef, accounting for one-third of global production. The main difference is that beef raised in the U.S. is primarily nourished on grains (corn, soybeans, and alfalfa), while beef produced in Brazil is mostly grassfed. In the U.S., the beef value chain has five major links:
- Animal Feed Suppliers: Producers of corn, soybean and alfalfa. Three companies produce nearly 40 million metric tons of feed annually.
- Cow-calf (ranching) Operations: calves are birthed, raised, and weaned on site. This stage of production is extremely fragmented, with over 700,000 farm operations across the U.S.
- Cattle feeding (feedlots): Cattle spend the last six months being fed a high-energy diet. Until recently, JBS, Tyson and Cargill owned about 95% of the feedlot capacity. However, since around 2020 most of the U.S. feedlot capacity is owned by private market firms.
- Meat packing and processing: There are only four companies that slaughter, cut and pack about 85% of all U.S. cattle.
- Food Retailers & Restaurants: About two-thirds of U.S. beef supply goes into food service—restaurants and cafeterias—while one-third is sold in supermarkets.
For each stage of the beef value chain, we use public company reports and government data to estimate profit margins. The table below summarizes each stage of production and relevant characteristics.
There are two key takeaways from the table above:
- With the exception of feed suppliers, each stage of production tends to deliver healthy profit margins, albeit it is the cow-calf operations (ranchers) that have the most variability (uncertainty) in profits.
- At least two stages in the value chain can be considered extremely concentrated. Four companies – JBS, Tyson, Cargill and NFC – control virtually all of the meatpacking in the U.S. and these companies tend to have the highest margins in the value chain.
Cracking the Cocoa Conundrum
Cocoa production is heavily concentrated in Ivory Coast and Ghana, which collectively account for nearly 60% of the world's production. The cocoa supply chain involves four distinct stages:
- Production: Cocoa is cultivated in plantations, then collected by collector members of cooperatives and processed at fermentation and drying centers to produce cocoa beans. Millions of farmers participate in this highly fragmented part of the chain.
- Processing, transport, trade and distribution: Beans are refined and ground to produce cocoa butter, cocoa liquor, and cocoa powder. Seven traders handle 62% of cocoa export volumes, making it a concentrated market.
- Manufacturing: Cocoa products are used by food manufacturers to produce chocolate confectionery and by industries such as cosmetics and pharmaceuticals. Mars, Hershey, Cargill, and Blommer—some of the world’s biggest chocolate manufacturers and processors—are headquartered in the U.S.
- Retail and consumption: Chocolate products are sold through food retailers and consumer outlets (grocery stores, wholesalers, and online).
As with beef, in the table below, we use public company reports and government data to estimate profit margins and we summarize each stage of production of cocoa and provide relevant characteristics.
Again, there are two key takeaways from the table above:
- While farmers receive a disproportionately small share of profits, manufacturers and retailers command a significant portion.
- Market concentration is exceptionally high in processing, trade, and manufacturing, with only a few major players dominating these sectors, while small-scale farmers bear the brunt of the risks at the production level. This concentration means that processing, trade, and manufacturing entities have the ability to diversify some of the risks they face, contrasting sharply with the vulnerability of small-scale farmers.
Investment Implications
So far, our analysis has shown that in the two foodstuffs we analyzed, there is at least one stage in the value chain that is completely dominated by a limited number of companies. In the cocoa chain, Mondelez, Olam, Cargill, Barry Callebaut and Nestle dominate. For beef, JBS, Tyson, and Cargill dominate meat processing, while ADM, Cargill and Bunge have the stronghold on animal feed production.
The table below revisits the initial eight foodstuffs analyzed by CERES and shows that there are a handful of companies involved in ALMOST EVERY food value chain.

In other words, there are select public companies that are likely to participate in virtually every meal of the typical western diet!
At the early stages in the value chain, ADM, Cargill, and Bunge are involved in all eight foodstuffs. At the transformation stage, Nestle, Mondelez and Kellogg are each involved in at least 50% of the foodstuffs.
From a consumers’ perspective, the realization that a mere handful of companies have such dominance in what we eat can be unsettling. However, from an investor’s perspective, particularly one that is concerned with sustainability, it is clear that influencing the operations of just a handful of companies can potentially have enormous impacts throughout our food system. In other words, food is an industry whereby aggressive investor engagement, when done at key links in the value chain, can be effective by concentrating efforts on just a short list of companies.
Engagement at the Agricultural Production Stage: ADM, Bunge and Cargill
ADM, Bunge and Cargill together are the main agribusiness companies that buy, trade, process and ship agricultural commodities such as corn, soybean, palm, wheat, etc. ADM and Bunge are both listed companies while Cargill is private. Another major difference is that ADM and Bunge have similar, elevated ESG scores across all material SASB categories (energy management, water management, product quality, employee safety, supply management, materials sourcing) while Cargill is severely lagging (in 2019, it was named the worst company in the world by Mighty Earth!)
That said, all three companies have a multitude of controversies; ADM scores a D- according to Refinitiv Eikon and Bunge is not much better with a C-. Controversies range from animal testing, workplace conditions, child labor, deforestation, shareholder rights, anticompetition and more.
Engagement at the Processing & Transformation Stage: Nestlé, Olam, Mondelez and JBS
Nestlé: Nestlé demonstrates comprehensive disclosures and proactive approaches to water management, energy efficiency, and product safety, and is considered better than its peers on these topics. However, they lack disclosures on corrective audits in supply chains, GMO products, and ingredient sourcing in regions with high water stress. Furthermore, Nestlé has faced a series of recent controversies (scoring a D according to Refinitiv Eikon), including lawsuits over anti-competition practices (infant formula), allegations of illegal water bottling (California), labor disputes and working condition controversies. They have long been accused of child labor in their cocoa supply chain and following stakeholders’ pressure, they announced a US$1.4 billion investment plan in 2022 to address the issue, even though there are limitations in their ability to effectively tackle this pervasive issue.
Olam Group Ltd: Olam provides operational disclosures that are slightly behind their peers, although the good news is this company is relatively free of controversies. However, they acknowledge that child labor remains a persistent issue in cocoa production. Olam relies on a vast network of suppliers spanning over 60 countries, with a direct and indirect supply base predominantly farmed by small-scale farmers in emerging markets. While the company is aware of child labor, their efforts remain paltry: they provide training on the topic to 240,000 farmers which represents a mere 5% of all farmers they work with.
Mondelez International: Mondelez stands out not only for its operational performance but also for its product portfolio, which primarily consists of highly-processed and sugary snacks. Unlike other companies mentioned, Mondelez specializes in indulgent treats that often contain high levels of sugar, unhealthy fats, and artificial additives. This focus contributes to potential health risks such as weight gain, obesity, diabetes, and heart disease associated with excessive consumption of these products. In addition to these concerns, Mondelez, like its peers, faces regular controversies, scoring a C- according to Refinitiv Eikon, regarding product recalls, data breaches, advertisement norms violations, and child labor in its supply chain.
JBS: JBS has been long-considered a major laggard on most ESG-related issues, with particularly low scores related to working conditions, human rights and its supply chain. But the company’s controversies go even beyond these issues and include environmental scandals, child labor issues and anti-competitive behaviour (Refinitiv Eikon ratings is a D). All of these areas are ripe for investor engagement.
Our hypothesis at the end of 2023 that the artificial intelligence hype had become extreme with respect to related stock valuations has not panned out so far in 2024. Not only did Nvidia’s stock price soar on last week’s earnings announcement, but the company’s CEO Jensen Huang has further fuelled excitement related to generative AI with his optimistic guidance, “[AI] Demand is surging worldwide across companies and nations… Auto, health, robotics, financial services… multibillion-dollar industries are embracing our generative AI”.
Although the valuations of many “AI companies” make our eyes water (NVIDIA is trading at 66 times earnings), there is certainly much to be excited about from a productivity perspective. After all, as we highlighted in our April 2023 note, “Finding Real Returns in Artificial Intelligence” ChatGPT displays an IQ of above 120, placing it among the top 10% of humans. This is quite the progress, given that less than a decade ago, researchers ranked Google’s AI IQ at 47, just shy of the average IQ (55) of a human 6-year-old. That said, for AI to make its way into all spheres of the economy like Internet did in the late 1990s, a massive economy-wide CAPEX effort will be needed – and as of now, that has yet to happen.
And what about from a sustainability perspective? There has been healthy debate (although perhaps not enough action) surrounding ethical aspects of AI. Questions have been raised about the energy intensity of AI tools, about data biases that are leading to discriminatory outcomes, about potential job losses, etc. On the flip side, AI promises to address challenges across industries, including resource optimization and medical breakthroughs. In short, artificial intelligence’s influence on our future is complex and heterogeneous. For investors looking to put capital to work beyond the semiconductor companies that have supplied AI with the chips to flourish, we note the key Sustainable Market Strategies’ themes where leveraging AI should produce superior real-world outcomes alongside superior returns.
Productivity with Purpose
With labor shortages persisting in many developed countries and an ever-increasing need to make better use of physical resources, the first major allure of artificial intelligence is its potential to increase productivity, either by replacing less efficient technologies (and/or labor) or via optimisation of resources.
Software companies were one of the “early movers” with respect to excitement in the application of AI tools. Indeed, four software companies with strong ESG credentials that have been widely lauded for their AI integration – Salesforce, ServiceNow, Adobe and Workday – have seen their stock prices jump between 70- 80% in the past year: a less stellar performance than Nvidia perhaps, but nonetheless extraordinary relative to the S&P500.
That said, investors would be justified if concerned that last year’s hype will not be repeated in 2024: ServiceNow and Workday both reported quarterly earnings in February and the stock market reaction was negative. Both companies disappointed on revenue growth. Investors seemed particularly underwhelmed by Workday’s announcement of the acquisition of an “AI talent solution company”. What is more, Workday has recently come under pressure for facilitating discriminatory biases with its existing AI tools. At valuations still sky high (the lowest P/E of these companies is Adobe at 47 times earnings!), it makes sense to look elsewhere for productive and sustainable applications of AI.
Beyond software, one area that we find exciting as an AI sustainability opportunity is in industrial automation and digital design. In our note last year, we screened for companies that were best positioned to leverage AI advances for purposeful applications, i.e. supporting decarbonization, optimizing physical resource use and improving safety in industries like energy and food production.
The companies we identified at the time were already making good use of artificial intelligence tools and this has continued, with several companies like Schneider Electric and Rockwell Automation announcing new partnerships with Microsoft to leverage their OpenAI tools.
- Rockwell Automation (ROK) provides automation and software solutions to the manufacturing sector, primarily in the U.S. Like many parts of the U.S. manufacturing sector, the company struggled over the past year with an inventory bulge and supply chain constraints, which have been reflected in the company’s muted stock price performance. With the U.S. manufacturing sector showing signs of revival (e.g. the ISM manufacturing survey has bottomed), companies like Rockwell offer an interesting entry point.
- Schneider Electric SE is an automation and energy management company, with about three-quarters of revenue generated from energy management and one-quarter from industrial automation. This makes the company particularly well-positioned to leverage AI advances for purposeful applications as well as to capitalize on the structural buildout of electricity grids (see last section below).
Leave No Person Behind
At Sustainable Market Strategies, investing to reduce social inequalities centers around three key ideas: improving health outcomes through greater access to care and medical breakthroughs, improving education and increasing labor fairness. Of these three sub-themes, we believe education is the area where artificial intelligence is already playing out in stock prices and where sustainability investors can leverage near-term trends.
Artificial intelligence apps, such as ChatGPT, are increasingly part of an educational toolbox just like calculators, and simple web searches. Artificial intelligence employs adaptive learning, intelligent content curation, and smart monitoring and reporting to teach skills: dozens of learning apps powered by AI have sprung up in recent months. One stand-out is Duolingo. The company’s main focus is on language learning, which is in high demand due to ever-increasing international worker flows and remote work. In a note last June “Education Stocks: Will ChatGPT Decide Who Passes or Fails”, we contended that Duolingo would be an AI winner. Since then, the company has added personalized language lessons fuelled by AI-powered feedback and has reached all-time high engagement rates, as measured by the activity of daily and monthly users. The stock price is up over 40% since our June note and Q4 earnings that were reported earlier this week confirm that the company is able attract paid subscribers to their products.
As for health care, this is the sector that holds the most promise for positive disruption from AI. Already, there are several research studies showing that AI can perform as well as or better than humans at some health care tasks. Studies show, for example, that patients often prefer responses to medical questions from chatbots over physicians, giving the chatbot higher ratings on both quality and empathy!
But the best medical use cases of AI involve settings where large data sets (especially images) that can be applied to well-defined problems are available. Diagnosing diseases, by reviewing X-rays for example, is a very effective use of AI. Companies like Quest Diagnostics, which offers access to diagnostic testing services for cancer, cardiovascular disease, neurological disorders, already leverage AI in their diagnostic tools, most notably for dementia.
A major risk, however, is that current medical AI tools tend to amplify existing discriminative biases in health care outcomes: since AI-based health care technology depends on the data that it is fed, a lack of representative data risks leading to biased models that ultimately produce incorrect health assessments especially according to race. Moreover, although the health care sector is heavily regulated, no regulations directly target the use of AI in medical devices. This is likely to change and will significantly alter the risk/reward profile of health care companies actively investing in AI tools.
Finally, in terms of labor fairness, there remain many challenges to ensure that AI tools do not accentuate existing cognitive biases. In addition, at a macro level, there are good odds that artificial intelligence will impact income inequality in ways similar to previous technology booms: if AI is levered mainly to increase automation, then a widening in the gap between capital and labor and between the professional class and other workers is likely.
A recent Pew survey in the U.S. is illustrative: the survey showed that workers with a university education are twice as likely as those without to be exposed to AI in their jobs. These same workers were far more likely to say that AI will help them more than hurt them in their jobs. On the flipside, retail trade, construction and accommodation and food services are all industries where workers are unlikely to see much benefit from AI tools and are also at risk of being replaced by technology. These are industries that tend to be lower wage jobs with low levels of unionization or other worker protections. In other words, there is some evidence to suggest that gains from artificial intelligence will accrue in already high-paying sectors and largely bypass and/or harm employment in lower paying industries. It is challenging to find AI focused investment ideas related to alleviating income/labor fairness, particularly since, as described above, some of the best company software tools (Salesforce, Workday) allegedly create increased discriminatory biases.
Achieving The Energy Transition
Artificial intelligence is a voracious consumer of energy. An oft-quoted study published in late 2023 projects that based on current and future sales of Nvidia microchips specifically for AI, the amount of electricity required to power the world’s data centers could jump by 50% by 2027, thanks to AI alone. According to the study, that’s about the power consumption of the Netherlands, and would require the entire output of about 15 average-size nuclear power plants.
Many companies are working on smaller, less power-hungry AI models that, but even if AI-related energy is half of the current estimate, it will require substantial increases in power production. Most problematic is that the energy “needs” of AI are arriving at a time when renewable energy supply is still falling short of overall energy demand: without the complicating factor of AI, the energy transition is already a massive challenge.
To be sure, artificial intelligence can be used to make the grid smarter and optimize energy usage. But it’s likely that over the next five years, demand from the production of data across industries will far outpace energy savings from optimization within the energy sector.
Crucially, it is the demands on distribution and transmission of electricity (i.e. the grid) that is particularly challenged by artificial intelligence demands. Transporting electricity from where it is produced to where data centres are desired requires a buildout of the electricity grid.
This problem is particularly acute in North America, where grid planners have recently nearly doubled their 5-year load growth forecast; in the U.S. electricity demand is now expected to increase by 4.7% over the next five years. By way of comparison, over the past decade, grid planners have been forecasting a mere 0.5% annual growth rate.
We see this as a major bottleneck for artificial intelligence usage and a major opportunity for companies involved in the buildout of energy transmission. Schneider Electric, Eaton Corporation, ABB, Nexans, Prysmian should become household names for investors that want exposure to the energy transition.